Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 13:3:47.
doi: 10.3389/fonc.2013.00047. eCollection 2013.

Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target

Hua Li  1 , Rugang Zhang
Affiliations

Role of EZH2 in Epithelial Ovarian Cancer: From Biological Insights to Therapeutic Target

Hua Li et al. Front Oncol. .

Abstract

EZH2 is the catalytic subunit of polycomb repressive complex 2 (PRC2), which generates a methylation epigenetic mark at lysine 27 residue of histone H3 (H3K27me3) to silence gene expression. EZH2 target genes are involved in a variety of biological processes such as stem cell pluripotency, cell proliferation, and oncogenic transformation. EZH2 is often over-expressed in epithelial ovarian cancer (EOC) cells and in ovarian cancer-associated stromal endothelial cells. Notably, EZH2 promotes cell proliferation, inhibits apoptosis and enhances angiogenesis in EOCs. In contrast to genetic alterations, which are typically non-reversible, epigenetic alterations are reversible. Thus, inhibiting EZH2/PRC2 activity represents an attractive strategy for developing ovarian cancer therapeutics by targeting both ovarian cancer cells and ovarian tumor microenvironment. Here we discuss the progress recently obtained in understanding how EZH2/PRC2 promotes malignant phenotypes of EOC. In addition, we focus on strategies for targeting EZH2/PRC2 to develop novel EOC epigenetic therapeutics.

Keywords: EZH2; EZH2 inhibitors; PRC2; epigenetic therapeutics; epithelial ovarian cancer.

PubMed Disclaimer

References

    1. Agger K., Cloos P. A., Christensen J., Pasini D., Rose S., Rappsilber J., et al. (2007). UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449, 731–73410.1038/nature06145 - DOI - PubMed
    1. Altomare D. A., Wang H. Q., Skele K. L., De Rienzo A., Klein-Szanto A. J., Godwin A. K., et al. (2004). AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23, 5853–585710.1038/sj.onc.1207721 - DOI - PubMed
    1. American Cancer Society. (2012). Cancer Facts & Figures 2012. Atlanta: American Cancer Society
    1. Ballare C., Lange M., Lapinaite A., Martin G. M., Morey L., Pascual G., et al. (2012). Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activity. Nat. Struct. Mol. Biol. 19, 1257–126510.1038/nsmb.2434 - DOI - PMC - PubMed
    1. Bodor C., O’Riain C., Wrench D., Matthews J., Iyengar S., Tayyib H., et al. (2011). EZH2 Y641 mutations in follicular lymphoma. Leukemia 25, 726–72910.1038/leu.2010.311 - DOI - PubMed